NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the Gerbil forced swim test

Neuropharmacology

Volumn 73, Issue , 2013, Pages 232-240

  Lelas, Snjezana ^a   Li, Yu Wen ^a   Wallace Boone, Tanya L ^a,b   Taber, Matthew T ^a   Newton, Amy E ^a   Pieschl, Rick L ^a   Davis, Carl D ^a,c   Molski, Thaddeus F ^a   Newberry, Kimberly S ^a   Parker, Michael F ^a   Gillman, Kevin W ^a   Bronson, Joanne J ^a   Macor, John E ^a   Lodge, Nicholas J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b SRI INTERNATIONAL   (United States)

^c AMGEN INC   (United States)

Author keywords

BMS 795176; Depression; Gerbil; Neurokinin 1 receptor; Occupancy; Serotonin transporter

Indexed keywords

3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; APREPITANT; BMS 795176; CITALOPRAM; FLUOXETINE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; FORCED SWIMMING TEST; GERBIL; HUMAN; HUMAN CELL; IMMOBILITY; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; STRUCTURE ANALYSIS;

BMS-795176; DEPRESSION; GERBIL; NEUROKININ-1 RECEPTOR; OCCUPANCY; SEROTONIN TRANSPORTER;

ANIMALS; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLUOXETINE; GERBILLINAE; HEK293 CELLS; HUMANS; IMMOBILITY RESPONSE, TONIC; MALE; MORPHOLINES; NEUROKININ-1 RECEPTOR ANTAGONISTS; PIPERIDINES; PREFRONTAL CORTEX; RADIOLIGAND ASSAY; RECEPTORS, NEUROKININ-1; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84885169431     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.05.038     Document Type: Article

References (29)

1. Campos, D., Pereira, J.R., Reinhardt, R.R., Carracedo, C., Poli, S., Vogel, C., Martinez-Cedillo, J., Erazo, A., Wittreich, J., Eriksson, L.O., Carides, A.D., Gertz, N.J., 2001. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. 19, 1759-1767.
2. Cascade, E., Kalali, A.H., Kennedy, S.H., 2009. Real-world data on SSRI antidepressant side effects. Psychiatry 6, 16-18.
3. Chenu, F., Guiard, B.P., Bourin, M., Gardier, A.M., 2006. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Brain Res. 172, 253-263.
4. Clayton, A.H., McGarvey, E.L., Abouesh, A.I., Pinkerton, R.C., 2001. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J. Clin. Psychiatry 62, 185-190.
5. Connolly, K.V., Thase, M.E., 2012. Emerging drugs for major depressive disorder. Expert Opin. Emerg. Drugs 17, 105-126.
6. Dawson, L.A., Watson, J.M., 2009. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci. Ther. 15, 107-117.
7. Ebner, K., Rupniak, N.M., Saria, A., Singewald, N., 2004. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl. Acad. Sci. U. S. A. 101, 4280-4285.
8. Froger, N., Gardier, A.M., Moratalla, R., Alberti, I., Lena, I., Boni, C., De Felipe, C., Rupniak, N.M., Hunt, S.P., Jacquot, C., Hamon, M., Lanfumey, L., 2001. 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J. Neurosci. 21, 8188-8197.
9. Geracioti, T.D., Carpenter, L.L., Owens, M.J., Baker, D.G., Ekhator, N.N., Horn, P.S., Strawn, J.R., Sanacora, G., Kinkead, B., Price, L.H., Nemeroff, C.B., 2006. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am. J. Psychiatry 163, 637-643.
10. Gillman, K.W., Parker, M.F., Silva, M., Degnan, A.P., Tora, G.O., Lodge, N.J., Li, Y-W., Lelas, S., Taber, M., Krause, R.G., Bertekap, R.L., Newton, A.E., Pieschl, R.L., Lengyel, K.D., Johnson, K.A., Taylor, S.J., Bronson, J.J., Macor, J.E., 2013. Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression. Bioorg. Med. Chem. Lett. 23, 407-411.
11. Gobbi, G., Cassano, T., Radja, F., Morgese, M.G., Cuomo, V., Santarelli, L., Hen, R., Blier, P., 2007. Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. Eur. Neuropsychopharmacol. 17, 328-338.
12. 3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain. Br. J. Pharmacol. 148, 39-45.
13. Guiard, B.P., Przybylski, C., Guilloux, J.-P., Seif, I., Froger, N., De Felipe, C., Hunt, S.P., Lanfumey, L., Gardier, A.M., 2004. Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J. Neurochem. 89, 54-63.
14. Harmer, C.J., Dawson, G.R., Dourish, C.T., Favaron, E., Parsons, E., Fiore, M., Zucchetto, M., Bifone, A., Poggesi, I., Fernandes, S., Alexander, R.C., Goodwin, G.M., 2013. Combined NK1 antagonism and serotonin reuptake inhibition: effects on emotional processing in humans. J. Psychopharmacol. 27, 435-443.
15. Hughes, Z.A., Starr, K.R., Langmead, C.J., Hill, M., Bartoszyk, G.D., Hagan, J.J., Middlemiss, D.N., Dawson, L.A., 2005. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur. J. Pharmacol. 510, 49-57.
16. Institute of Laboratory Animal Resources, 1996. Guide for the Care and Use of Laboratory Animals, seventh ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
17. Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., Reines, S., 2006. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59, 216-223.
18. Kramer, M.S., Winokur, A., Kelsey, J., Preskorn, S.H., Rothschild, A.J., Snavely, D., Ghosh, K., Ball, W.A., Reines, S.A., Munjack, D., Apter, J.T., Cunningham, L., King, M., Bari, M., Getson, A., Lee, Y., 2004. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29, 385-392.
19. Leffler, A., Ahlstedt, I., Engberg, S., Svensson, A., Billger, M., Oberg, L., Bjursell, M.K., Lindstrom, E., von Mentzer, B., 2009. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem. Pharmacol. 77, 1522-1530.
20. Marcus, R.N., McQuade, R.D., Carson, W.H., Hennicken, D., Fava, M., Simon, J.S., Trivedi, M.H., Thase, M.E., Berman, R.M., 2008. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder. J. Clin. Psychopharmacol., 28, 156-28, 165.
21. Meyer, J.H., 2007. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J. Psychiatry Neurosci. 32, 86-102.
22. Millan, M.J., Dekeyne, A., Gobert, A., Mannoury la Cour, C., Brocco, M., Rivet, J.-M., Di Cara, B., Lejeune, F., Cremers, T.I., Flik, G., de Jong, T.R., Olivier, B., de Nanteuil, G., 2010. S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine. Eur. Neuropsychopharmacol. 20, 599-621.
23. Owens, M.J., Morgan, W.N., Plott, S.J., Nemeroff, C.B., 1997. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283, 1305-1322.
24. Paul, I.A., 2001. Excitatory amino acid signalling, major depression and the actions of antidepressants. Pharm. News 8, 33-44.
25. Ratti, E., Bellew, K., Bettica, P., Bryson, H., Zamuner, S., Archer, G., Squassante, L., Bye, A., Trist, D., Krishnan, K.R., Fernandes, S., 2011. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1receptor antagonist casopitant in patients with major depressive disorder. J. Clin. Psychopharmacol. 31, 727-733.
26. *D report. Am. J. Psychiatry 163, 1905-1917.
27. Ryckmans, T., Berton, O., Grimé, R., Kogej, T., Lamberty, Y., Pasau, P., Talaga, P., Genicot, C., 2002. Dual NK1 antagonistsdserotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives. Bioorg. Med. Chem. Lett. 12, 3195-3198.
28. Varty, G.B., Cohen-Williams, M.E., Morgan, C.A., Pylak, U., Duffy, R.A., Lachowicz, J.E., Carey, G.J., Coffin, V.L., 2002. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27, 371-379.
29. Wallace-Boone, T.L., Newton, A.E., Wright, R.N., Lodge, N.J., McElroy, J.F., 2008. Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists. Neuropsychopharmacology 33, 1919-1928.